ATE511392T1 - Verzögert freigesetzte orale dosierungsformen eines prodrugs von r-baclofen und behandlungsverfahren damit - Google Patents

Verzögert freigesetzte orale dosierungsformen eines prodrugs von r-baclofen und behandlungsverfahren damit

Info

Publication number
ATE511392T1
ATE511392T1 AT08727550T AT08727550T ATE511392T1 AT E511392 T1 ATE511392 T1 AT E511392T1 AT 08727550 T AT08727550 T AT 08727550T AT 08727550 T AT08727550 T AT 08727550T AT E511392 T1 ATE511392 T1 AT E511392T1
Authority
AT
Austria
Prior art keywords
dosage forms
baclofen
methods
oral dosage
prodrug
Prior art date
Application number
AT08727550T
Other languages
English (en)
Inventor
David Kidney
Kenneth Cundy
Srikonda Sastry
Manshiu Leung
Original Assignee
Xenoport Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xenoport Inc filed Critical Xenoport Inc
Application granted granted Critical
Publication of ATE511392T1 publication Critical patent/ATE511392T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT08727550T 2007-01-11 2008-01-10 Verzögert freigesetzte orale dosierungsformen eines prodrugs von r-baclofen und behandlungsverfahren damit ATE511392T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US88459807P 2007-01-11 2007-01-11
PCT/US2008/050796 WO2008086492A1 (en) 2007-01-11 2008-01-10 Sustained release oral dosage forms of a prodrug of r-baclofen and methods of treatment

Publications (1)

Publication Number Publication Date
ATE511392T1 true ATE511392T1 (de) 2011-06-15

Family

ID=39432550

Family Applications (1)

Application Number Title Priority Date Filing Date
AT08727550T ATE511392T1 (de) 2007-01-11 2008-01-10 Verzögert freigesetzte orale dosierungsformen eines prodrugs von r-baclofen und behandlungsverfahren damit

Country Status (8)

Country Link
US (1) US20080206332A1 (de)
EP (1) EP2117517B1 (de)
JP (1) JP2010515754A (de)
AT (1) ATE511392T1 (de)
CA (1) CA2674610C (de)
ES (1) ES2365574T3 (de)
TW (1) TWI369982B (de)
WO (1) WO2008086492A1 (de)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004272111A1 (en) * 2003-09-11 2005-03-24 Xenoport, Inc. Treating and/or preventing urinary incontinence using prodrugs of GABA analogs
CA2584338C (en) 2004-11-04 2013-08-06 Xenoport, Inc. Gabapentin prodrug sustained release oral dosage forms
US20090118365A1 (en) * 2007-11-06 2009-05-07 Xenoport, Inc Use of Prodrugs of GABA B Agonists for Treating Neuropathic and Musculoskeletal Pain
EP2065038A1 (de) 2007-11-30 2009-06-03 Pharnext Neue therapeutische Ansätze zur Behandlung der Charcot-Marie-Tooth Krankheit
CN102300463B (zh) * 2008-12-04 2015-03-25 英特药业有限公司 扎来普隆(zaleplon)胃滞留药物传递系统
CN102341099A (zh) * 2009-03-03 2012-02-01 什诺波特有限公司 R-巴氯芬前药的持续释放口服剂型
JP2012524065A (ja) * 2009-04-17 2012-10-11 ゼノポート，インコーポレーテッド ＧＡＢＡＢ受容体リガンドとしてのγ−アミノ酪酸誘導体
US9393241B2 (en) * 2009-06-02 2016-07-19 Pharnext Compositions for treating CMT and related disorders
EP2263665A1 (de) 2009-06-02 2010-12-22 Pharnext Neue Zusammensetzungen zur Behandlung von CMT und verwandten Erkrankungen
US8673340B2 (en) * 2009-09-10 2014-03-18 Boston Foundation For Sight Sodium channel blocker delivery system with scleral lens
US10786464B2 (en) 2009-11-03 2020-09-29 Lupin Limited Modified release formulation of lacosamide
WO2011079074A1 (en) * 2009-12-24 2011-06-30 Acura Phamaceuticals, Inc. Pharmaceutical compositions for deterring misuse, abuse, and diversion
CA2790164A1 (en) 2010-02-17 2011-08-25 Sun Pharma Advanced Research Company Ltd. Method of treating a disease condition susceptible to baclofen therapy
WO2011101863A2 (en) * 2010-02-19 2011-08-25 Cadila Healthcare Limited Extended release pharmaceutical compositions of lacosamide
US8377956B2 (en) * 2010-03-01 2013-02-19 Xenoport, Inc. Use of (3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(4-chlorophenyl) butanoic acid for treating urinary incontinence
EP2468261A1 (de) 2010-12-02 2012-06-27 UCB Pharma GmbH Formulierung von Lacosamid
WO2012072256A2 (en) 2010-12-02 2012-06-07 Ucb Pharma Gmbh Once daily formulation of lacosamide
PT2560631E (pt) 2011-03-01 2014-02-24 Pharnext Terapia à base de baclofeno e acamprosato de distúrbios neurológicos
US9248111B2 (en) 2011-03-01 2016-02-02 Pharnext Therapeutic approaches for treating parkinson's disease
EP2705842A1 (de) 2012-09-05 2014-03-12 Pharnext Therapeutische Ansätze zur Behandlung von Morbus Parkinson
UA113165C2 (xx) 2011-03-01 2016-12-26 Застосування комбінації баклофену і акампросату для лікування неврологічних захворювань та композиція, яка містить баклофен і акампросат
US8580850B2 (en) 2011-08-11 2013-11-12 Xenoport, Inc. Anhydrous and hemihydrate crystalline forms of an (R)-baclofen prodrug, methods of synthesis and methods of use
US9180108B2 (en) 2011-10-27 2015-11-10 Medtronic, Inc. Baclofen formulations and methods for making same
CA2874737A1 (en) * 2012-06-01 2013-12-05 Lynn Health Science Institute, Inc. Use of baclofen to treat insomnia
AU2013291970B2 (en) 2012-07-18 2017-09-28 Pharnext Baclofen and acamprosate based therapy of Macular Degeneration disorders
EP2705841A1 (de) 2012-09-05 2014-03-12 Pharnext Kombinierungen aus Nootropikagenten zur Behandlung von kognitiven Dysfunktionen
EP2705843A1 (de) 2012-09-05 2014-03-12 Pharnext Therapeutische Ansätze zur Behandlung von Epilepsie und zugehöriger Erkrankungen durch Reduzierung der Epileptogenese
WO2014145195A1 (en) 2013-03-15 2014-09-18 Cerovene, Inc. Pharmaceuticals comprising a ph-dependent component and ph-raising agent
CA2913331C (en) 2013-06-05 2021-08-24 Pharnext Stable oral solutions for combined api
KR20160111013A (ko) 2014-02-11 2016-09-23 파넥스트 신경질환의 치료를 위한 바클로펜, 아캄프로세이트 및 중쇄 트리-글리세리드의 조합
AR101476A1 (es) 2014-08-07 2016-12-21 Acerta Pharma Bv Métodos para tratar cánceres, enfermedades inmunes y autoinmunes, y enfermedades inflamatorias en base a la tasa de ocupación de la tirosin quinasa de bruton (btk) y a la tasa de resíntesis de la tirosin quinasa de bruton (btk)
US10172800B2 (en) 2015-02-20 2019-01-08 Osmotica Kereskedelmi Es Szolgaltato Kft Controlled release dosage form with enhanced pharmacokinetics
US10300032B2 (en) 2015-02-20 2019-05-28 Osmotica Kereskedelmi Es Szolgaltato Kft Controlled release dosage form
US10987328B2 (en) 2015-02-20 2021-04-27 Osmotica Kereskedelmi Es Szolgaltato Kft Controlled release dosage form
US9579289B2 (en) 2015-02-20 2017-02-28 Osmotica Kereskedelmi Es Szolgaltato Kft Controlled release dosage form
MX2018008021A (es) 2015-12-30 2018-11-09 Adamas Pharmaceuticals Inc Metodos y composiciones para el tratamiento de trastornos relacionados con convulsiones.
WO2017134280A1 (en) * 2016-02-05 2017-08-10 Pharnext Novel combinatorial therapies of neurological disorders
US10383870B2 (en) 2016-06-10 2019-08-20 Pharnext Early treatment of CMT disease
EP3615017A1 (de) 2017-04-24 2020-03-04 Pharnext Auf idalopirdin basierende kombinationstherapien für morbus alzheimer
MX2020003400A (es) 2017-10-20 2020-09-18 Eagle Res Labs Limited Profarmacos de dantroleno y metodos de su uso.
AU2019211135A1 (en) 2018-01-29 2020-08-06 Pharnext Baclofen and acamprosate based therapy of alzheimer's disease in patients having lost responsiveness to acetylcholinesterase inhibitor therapy
DK3760190T3 (da) 2019-07-03 2023-09-04 Alvogen Inc Tabletter af pregabalin med forlænget frigivelse, fremgangsmåde til fremstilling og fremgangsmåde til anvendelse deraf

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4126684A (en) * 1976-02-11 1978-11-21 Ciba-Geigy Corporation 4-amino-3-p-halophenylbutyric acids and their derivatives used in the control of narcotic abuse
US5006560A (en) * 1989-12-20 1991-04-09 Schering Corporation Use of GABA-B selective agonists as anti-tussive agents
GB9308430D0 (en) * 1993-04-23 1993-06-09 Glaxo Group Ltd Medicaments
SE9603408D0 (sv) * 1996-09-18 1996-09-18 Astra Ab Medical use
US6992076B2 (en) * 2000-10-06 2006-01-31 Xenoport, Inc. Bile-acid derived compounds for providing sustained systemic concentrations of drugs after oral administration
US7232924B2 (en) * 2001-06-11 2007-06-19 Xenoport, Inc. Methods for synthesis of acyloxyalkyl derivatives of GABA analogs
US6818787B2 (en) * 2001-06-11 2004-11-16 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US7186855B2 (en) * 2001-06-11 2007-03-06 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US8048917B2 (en) * 2005-04-06 2011-11-01 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
JP2005527466A (ja) * 2001-08-09 2005-09-15 イーライ・リリー・アンド・カンパニー ｓＰＬＡ２インヒビターとしてのシクロヘプトＢインドール誘導体
EP1485082A4 (de) * 2002-02-19 2009-12-30 Xenoport Inc Syntheseverfahren für prodrugs von 1-acyl-alkyl derivaten und ihre zusammensetzungen
KR20050119676A (ko) * 2003-03-31 2005-12-21 제노포트 인코포레이티드 가바 유사체의 프로드러그를 사용한 열성 홍조의 치료 또는예방
US7662987B2 (en) * 2003-07-15 2010-02-16 Xenoport, Inc. Methods for synthesis of acyloxyalkyl compounds
MXPA06001876A (es) * 2003-08-20 2006-05-17 Xenoport Inc Prodrogas de aciloxialquil carbamato, metodos de sintesis y uso.
AU2004272111A1 (en) * 2003-09-11 2005-03-24 Xenoport, Inc. Treating and/or preventing urinary incontinence using prodrugs of GABA analogs
SG146643A1 (en) * 2003-09-17 2008-10-30 Xenoport Inc Treating or preventing restless legs syndrome using prodrugs of gaba analogs
PL1677767T3 (pl) * 2003-10-14 2011-12-30 Xenoport Inc Krystaliczna postać analogu kwasu gamma-aminomasłowego
US7227028B2 (en) * 2003-12-30 2007-06-05 Xenoport, Inc. Synthesis of acyloxyalkyl carbamate prodrugs and intermediates thereof
MXPA06011322A (es) * 2004-04-02 2007-02-21 Impax Laboratories Inc Formas de dosificacion farmaceutica que tienen propiedades de liberacion inmediata y/o liberacion controlada que contienen un agonista del receptor gabab.
CA2584338C (en) * 2004-11-04 2013-08-06 Xenoport, Inc. Gabapentin prodrug sustained release oral dosage forms
WO2008011016A2 (en) * 2006-07-18 2008-01-24 Dynogen Pharmaceuticals, Inc. Treating gastroesophageal reflux disease with 5-ht3- and gaba receptor agonists
WO2008060572A1 (en) * 2006-11-14 2008-05-22 Xenoport, Inc. Use of gabapentin and pregabalin prodrugs for treating tinnitus
AU2007332904A1 (en) * 2006-12-08 2008-06-19 Xenoport, Inc. Use of prodrugs of GABA analogs for treating diseases

Also Published As

Publication number Publication date
TW200900054A (en) 2009-01-01
EP2117517A1 (de) 2009-11-18
EP2117517B1 (de) 2011-06-01
CA2674610A1 (en) 2008-07-17
TWI369982B (en) 2012-08-11
JP2010515754A (ja) 2010-05-13
CA2674610C (en) 2013-06-18
ES2365574T3 (es) 2011-10-07
US20080206332A1 (en) 2008-08-28
WO2008086492A1 (en) 2008-07-17

Similar Documents

Publication Publication Date Title
ATE511392T1 (de) Verzögert freigesetzte orale dosierungsformen eines prodrugs von r-baclofen und behandlungsverfahren damit
CY1121593T1 (el) Προφαρμακα της τετραϋδροκανναβινολης, συνθεσεις οι οποιες περιλαμβανουν προφαρμακα της τετραϋδροκανναβινολης και μεθοδοι χρησης των ιδιων
DK2023918T3 (da) Cyclosporiner til behandlingen og forebyggelse af okulære lidelser
EA201791669A3 (ru) Новые терапевтические подходы в лечении смт и связанных с ней расстройств
CR20210368A (es) Combinación de dextrometorfano y bupropión para el tratamiento de depresión
MX374396B (es) Rocio de fentanilo sublingual.
EA201170249A1 (ru) 3,4-диарилпиразолы в качестве ингибиторов протеинкиназ
EA201490949A1 (ru) Ингибиторы киназ
CY1114139T1 (el) Πλακιδιο βουπρενορφινης για τη θεραπεια υποκαταστασης ναρκωτικων
MX347106B (es) Coposiciones farmacéuticas de liberación inmediata que comprenden oxicodona y naloxona.
NO20076508L (no) Acyloksykarbamat prodroger av traneksaminsyre og fremgangsmater for fremstilling og anvendelse derav
EA200870254A1 (ru) Способ лечения воспалительных заболеваний
UY30377A1 (es) Inhibidores triciclicos fusionados de sulfonamida de gama-secretasa
MX2010002735A (es) Envase de titulacion para neramexano y su uso en el tratamiento de un trastorno del oido interno.
CY1115381T1 (el) Διενυδρη υδροχλωρικη ναλμεφαινη
WO2011056240A3 (en) Pharmaceutical compositions and oral dosage forms of a levodopa prodrug and methods of use
ATE554084T1 (de) N-hydroxyacrylamidverbindungen
EA200970483A1 (ru) Применение пролекарств габапентина и прегабалина для лечения шума в ушах
AR062401A1 (es) Uso de derivados del 2,5-dihidroxibenceno para tratar dermatitis
CY1112770T1 (el) Αναστολεις κινασης και μεθοδοι χρησης τους
MX2019006721A (es) Tratamiento para la colangitis biliar primaria.
MX2012013879A (es) Derivados de hidroxipiridona, composiciones farmceuticas de los mismos y su uso terapeutico para tratar enfermedades proliferativas.
CY1114760T1 (el) Θεραπευτικη αγωγη αθηροσκληρωσης
ATE522500T1 (de) Amidderivate als ionenkanalliganden sowie pharmazeutische zusammensetzungen und verwendungsverfahren dafür
MA32841B1 (fr) Composés de cycloundeca depsipeptides et leur utilisation comme médicament

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties